Health 20 sources · today 27 articles

Moderna shares plunge after cancer vaccine data leak unsettles investors

Moderna shares fell about 25% after partial melanoma vaccine data circulated online, even as fuller results showed benefits from the treatment developed with Merck.

Read the full story → · Latest coverage 23 Oct 2026, 3:15 pm UTC

Key moments · 6

Unverified vaccine report circulates on social platform X

ABC ↗

Moderna shares plunge about 25%, reversing vaccine optimism

Forbes ↗

Full trial data released later Thursday appear positive

CNBC ↗

Coverage gives conflicting figures for the reported benefit

Financial Times ↗

Reports detail 42% reduction in melanoma recurrence or death

CNN Brasil ↗

New coverage reports reduced risk of melanoma spreading

Times now ↗

Coverage by day

newest first

13 articles

  1. Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction
    CNBC
  2. Analysts weigh in on Moderna's big drop following cancer vaccine results
    Breaking News on Seeking Alpha Business & Economy
  3. A novel mRNA cancer vaccine helps cut the chances of melanoma tumor recurrence in major study
    CBC News
  4. Personalised cancer vaccine expected to be approved next year
    New Scientist
  5. World's First Cancer Vaccine Cuts Melanoma Recurrence Risk By 42%, Cancer Spread Risk By 38%
    Times now

16 articles

  1. A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%
    TIME.com
  2. ‘Landmark moment’: Sydney scientist’s world-first cancer breakthrough revealed
    Sydney Morning Herald
  3. Here’s what Moderna’s latest mRNA cancer vaccine data actually show
    Scientific American Content: Global Science
  4. A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning
    Top Stories
  5. Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
    Ars Technica Tech